Literature DB >> 28279966

Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.

Teresa M Brophy1, Soracha E Ward1, Thomas R McGimsey1, Sonja Schneppenheim1, Clive Drakeford1, Jamie M O'Sullivan1, Alain Chion1, Ulrich Budde1, James S O'Donnell2.   

Abstract

OBJECTIVE: Previous studies have demonstrated a role for plasmin in regulating plasma von Willebrand factor (VWF) multimer composition. Moreover, emerging data have shown that plasmin-induced cleavage of VWF is of particular importance in specific pathological states. Interestingly, plasmin has been successfully used as an alternative to ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif) in a mouse model of thrombotic thrombocytopenic purpura. Consequently, elucidating the molecular mechanisms through which plasmin binds and cleaves VWF is not only of basic scientific interest but also of direct clinical importance. Our aim was to investigate factors that modulate the susceptibility of human VWF to proteolysis by plasmin. APPROACH AND
RESULTS: We have adapted the VWF vortex proteolysis assay to allow for time-dependent shear exposure studies. We show that globular VWF is resistant to plasmin cleavage under static conditions, but is readily cleaved by plasmin under shear. Although both plasmin and ADAMTS13 cleave VWF in a shear-dependent manner, plasmin does not cleave at the Tyr1605-Met1606 ADAMTS13 proteolytic site in the A2 domain. Rather under shear stress conditions, or in the presence of denaturants, such as urea or ristocetin, plasmin cleaves the K1491-R1492 peptide bond within the VWF A1-A2 linker region. Finally, we demonstrate that VWF susceptibility to plasmin proteolysis at K1491-R1492 is modulated by local N-linked glycan expression within A1A2A3, and specifically inhibited by heparin binding to the A1 domain.
CONCLUSIONS: Improved understanding of the plasmin-VWF interaction offers exciting opportunities to develop novel adjunctive therapies for the treatment of refractory thrombotic thrombocytopenic purpura.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  glycosylation; heparin; plasmin; shear; von Willebrand factor

Mesh:

Substances:

Year:  2017        PMID: 28279966     DOI: 10.1161/ATVBAHA.116.308524

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  11 in total

1.  Protease Activity in Vascular Disease.

Authors:  Megan A Slack; Scott M Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-25       Impact factor: 8.311

Review 2.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

3.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

4.  Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.

Authors:  Alexander Tischer; Maria A Brehm; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Katelynn J Nelton; Rachel R Leger; Tobias Obser; Marina Martinez-Vargas; Steven T Whitten; Dong Chen; Rajiv K Pruthi; H Robert Bergen; Miguel A Cruz; Reinhard Schneppenheim; Matthew Auton
Journal:  J Mol Biol       Date:  2019-10-17       Impact factor: 5.469

5.  ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.

Authors:  Soracha E Ward; Helen Fogarty; Ellie Karampini; Michelle Lavin; Sonja Schneppenheim; Rita Dittmer; Hannah Morrin; Siobhan Glavey; Cliona Ni Cheallaigh; Colm Bergin; Ignacio Martin-Loeches; Patrick W Mallon; Gerard F Curley; Ross I Baker; Ulrich Budde; Jamie M O'Sullivan; James S O'Donnell
Journal:  J Thromb Haemost       Date:  2021-06-20       Impact factor: 16.036

6.  Desialylation of O-glycans activates von Willebrand factor by destabilizing its autoinhibitory module.

Authors:  Kayleigh M Voos; Wenpeng Cao; Nicholas A Arce; Emily R Legan; Yingchun Wang; Asif Shajahan; Parastoo Azadi; Pete Lollar; Xiaohui Frank Zhang; Renhao Li
Journal:  J Thromb Haemost       Date:  2021-09-26       Impact factor: 16.036

7.  Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and Metalloproteinase With a Thrombospondin Type-1 Motif, Member 13).

Authors:  Maria Bortot; Katrina Ashworth; Alireza Sharifi; Faye Walker; Nathan C Crawford; Keith B Neeves; David Bark; Jorge Di Paola
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-11       Impact factor: 10.514

8.  High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group.

Authors:  Najla El Jurdi; Heba Elhusseini; Joan Beckman; Todd E DeFor; Grigori Okoev; John Rogosheske; Aleksandr Lazaryan; Kristen Weiler; Veronika Bachanova; Brian C Betts; Bruce R Blazar; Claudio G Brunstein; Fiona He; Shernan G Holtan; Murali Janakiram; Radhika Gangaraju; Joseph Maakaron; Margaret L MacMillan; Armin Rashidi; Erica D Warlick; Smita Bhatia; Gregory Vercellotti; Daniel J Weisdorf; Mukta Arora
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037

Review 9.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

10.  Novel therapies in thrombotic thrombocytopenic purpura.

Authors:  Camila Masias; Spero R Cataland
Journal:  Res Pract Thromb Haemost       Date:  2017-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.